Package Leaflet: Information for the Patient
Ziprasidone Krka 20 mg Hard Capsules EFG
Ziprasidone Krka 40 mg Hard Capsules EFG
Ziprasidone Krka 60 mg Hard Capsules EFG
Ziprasidone Krka 80 mg Hard Capsules EFG
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1. What Ziprasidone Krka is and what it is used for
2. What you need to know before you start taking Ziprasidone Krka
3. How to take Ziprasidone Krka
4. Possible side effects
5. Storage of Ziprasidone Krka
6. Contents of the pack and additional information
Ziprasidona Krkacapsules are a medication belonging to the group of medications known as antipsychotics.
Ziprasidonais indicated for the treatment of schizophrenia in adults, a mental illness characterized by the appearance of one or more of the following symptoms: hearing, seeing or feeling things that do not exist, believing in something that is not true, having unusual suspicions, being absent and having difficulty establishing social relationships, nervousness, depression or anxiety.
Furthermore,ziprasidonais used in adults and in children and adolescents from 10 to 17 years old for the treatment of symptoms of moderate severity mania or mixed in bipolar disorder, a mental illness characterized by alternating phases of euphoric mood states (mania) or depressed. During mania episodes, the most characteristic symptoms are: euphoric behavior, exaggerated self-esteem, increased energy, decreased need for sleep, lack of concentration or hyperactivity and repetition of risky behaviors.
Do not take Ziprasidona Krka
Warnings and precautions
Consult your doctor or pharmacist before starting to take ziprasidona.
Contact your doctor immediately if you experience any of the following symptoms:
Inform your doctor that you are taking Ziprasidona Krka capsules before undergoing any diagnostic tests (including blood, urine, liver function, heart rhythm tests, etc.) as it may alter the results.
Children and adolescents
The safety and efficacy of ziprasidona in the treatment of schizophrenia in children and adolescents have not been established.
Other medications and Ziprasidona Krka
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take other medications, including those purchased without a prescription.
DO NOT TAKE ZIPRASIDONA KRKAif you are taking medications for heart rhythm disturbances or medications that can affect heart rhythm, such as:
Consult your doctor or pharmacist before starting to take Ziprasidona Krka.
Inform your doctor or pharmacist if you are using or have used recently medications for:
See the section “Do not take Ziprasidona Krka” earlier.
Ziprasidona Krka with food and drinks
Ziprasidona Krka should be taken during main meals.
Do not consume alcoholic beverages during treatment with Ziprasidona Krka, as this may increase the risk of adverse effects.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Do not take Ziprasidona Krka during pregnancy unless your doctor tells you to, as this medication may harm your baby. Always use a suitable contraceptive method.
The following symptoms may occur in newborns, from mothers who have used Ziprasidona Krka in the last trimester (last three months of pregnancy): tremors, muscle stiffness and/or weakness, drowsiness, agitation, respiratory problems, and feeding difficulties. If your baby experiences any of these symptoms, you may need to contact your doctor.
Breastfeeding
Do not breastfeed your baby while taking Ziprasidona Krka, as small amounts may pass into breast milk.
If you plan to breastfeed your baby, inform your doctor before taking this medication.
Contraception
If you can become pregnant, you should use a suitable contraceptive method while taking this medication.
Driving and use of machines
Ziprasidona Krka may cause symptoms such as drowsiness, dizziness, or vision disturbances, and may decrease your reaction time. These effects, as well as the underlying disease, may make it difficult for you to drive vehicles or operate machines. Therefore, do not drive, operate machines, or engage in other activities that require special attention, until your doctor evaluates your response to this medication.
Important information about some of the components of Ziprasidona Krka
This medication contains lactose. If your doctor has told you that you have a lactose intolerance, consult with him before taking this medication.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The capsules should be taken with food and swallowed whole, without chewing, crushing, or opening beforehand. It is essential not to chew, crush, or open the capsules, as this may affect the point at which the medication is absorbed in the intestine.
Ziprasidone should be taken twice a day, one capsule in the morning during a consistent breakfast and one in the evening during dinner. Make sure to take this medication at the same time every day.
Adults
The recommended dose is 40 to 80 mg of ziprasidone twice a day with food.
Your doctor may adjust the dose in long-term treatments. It is recommended not to exceed the maximum dose of 160 mg per day.
Children and adolescents with bipolar mania
The recommended starting dose for treatment is 20 mg per day in a single dose with food, after which your doctor will indicate your optimal dose. It is recommended not to exceed the maximum dose established by weight range, 160 mg per day for children weighing 45 kg or more, and 80 mg per day for children weighing less than 45 kg.
The safety and efficacy of ziprasidone in the treatment of schizophrenia in children and adolescents have not been established.
Patients over 65 years old
If you are over 65 years old, your doctor will decide on the suitable dose for you. The dose for patients over 65 years old is sometimes lower than that used in younger people. Your doctor will indicate the appropriate dose for you.
Patients with liver problems
If you have liver problems, you may need to take a lower dose of ziprasidone. Your doctor will indicate the correct dose for you.
If you takemultiple Ziprasidone Krka capsules
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicological Information Service, phone 91.562.04.20, indicating the medication and the amount ingested. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
If you have taken too many capsules, you may experience drowsiness, tremors, seizures, and involuntary movements of the head and neck.
If youforgot to take Ziprasidone Krka
It is essential to take ziprasidone at the same time every day. If you forget to take a dose, take it as soon as you remember. However, if it is close to the next dose, skip the missed dose and take the next one at its scheduled time. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Ziprasidone Krka
Your doctor will indicate for how long you should take ziprasidone. Do not stop taking this medication unless your doctor tells you to.
It is essential to continue treatment even if you feel better. If you stop treatment too soon, symptoms may return.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
However, most side effects are transient. It can often be difficult to distinguish the symptoms of your illness from side effects.
STOP taking Ziprasidona Krka capsules and contact your doctor immediately if you experience any of the following serious side effects:
Frequent side effects (can affect up to 1 in 10 people)
Rare side effects (can affect up to 1 in 100 people):
Rare side effects (can affect up to 1 in 1,000 people):
You may experience some of the side effects mentioned below. These potential side effects are generally mild to moderate in nature and may
disappear over time. However, if the side effect is severe or persistent, contact your doctor.
Very frequent side effects (can affect more than 1 in 10 people):
Frequent side effects (can affect up to 1 in 10 people):
Rare side effects (can affect up to 1 in 100 people):
Rare side effects (can affect up to 1 in 1,000 people):
Unknown frequency (cannot be estimated from available data):
Additional side effects in children and adolescents
In clinical trials with children and adolescents, side effects were generally similar to those of adults (see above), except for sedation and somnolence, which were more frequent in children. The most common side effects in children and adolescents were sedation, somnolence, headache, fatigue, nausea, dizziness, vomiting, decreased appetite, and movement disorders.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicinal Products for Human Use Website:www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the reach and sight of children.
Do not store above 30°C.
Store in the original packaging to protect from humidity.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of packaging and unused medicines at the SIGRE point of the pharmacy. Ask your pharmacist how to dispose of unused packaging and medicines. This will help protect the environment.
Hard capsules of 20 mg
Each hard capsule contains 20 mg of ziprasidone as ziprasidone hydrochloride.
Hard capsules of 40 mg
Each hard capsule contains 40 mg of ziprasidone as ziprasidone hydrochloride.
Hard capsules of 60 mg
Each hard capsule contains 60 mg of ziprasidone as ziprasidone hydrochloride.
Hard capsules of 80 mg
Each hard capsule contains 80 mg of ziprasidone as ziprasidone hydrochloride.
The other components (excipients) are:
- inside the capsule: lactose monohydrate, pregelatinized maize starch, povidone K-25 and magnesium stearate and
- capsule body: titanium dioxide (E171), gelatin, indigo carmine (E132) andyellow iron oxide (E172). (See section 2 “Ziprasidone Krka contains lactose”)
Appearance ofZiprasidone Krkaand contents of the package
Hard capsules of 20 mg
The cap of the capsule is pale green and the capsule body is white. The capsule contains a slightly pink to brown powder.
Hard capsules of 40 mg
The cap of the capsule is dark green and the capsule body is pale green. The capsule contains a slightly pink to brown powder.
Hard capsules of 60 mg
The cap of the capsule is dark green and the capsule body is white. The capsule contains a slightly pink to brown powder.
Hard capsules of 60 mg
The cap of the capsule is pale green and the capsule body is white. The capsule contains a slightly pink to brown powder.
Packages of 14, 20, 28, 30, 50, 56, 60, 90 and 100 hard capsules in blisters are available.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain
This medicine is authorized in the member states of the European Economic Area with the following names:
Member State Name | Medicine Name |
Germany | Zipsilan |
Austria | Ziprasidon Krka |
Bulgaria | Zypsila |
Denmark | Ziprasidon Krka |
Estonia | Ypsila |
Finland | Ziprasidon Krka |
Czech Republic | Zypsilan |
Hungary | Ypsila |
Lithuania | Zypsilan |
Latvia | Ypsila |
Poland | Zypsila |
Slovenia | Zypsila |
Slovakia | Zypsilan |
Spain | Ziprasidona Krka |
Romania | Zypsila |
Sweden | Ziprasidon Krka |
Date of the last review of this leaflet:July 2024
More detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.